Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 184 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show April 28, 2021 Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health December 23, 2019 Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:... February 8, 2021 Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later August 15, 2018 Load more HOT NEWS Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma... Maintenance Therapy with CC-486 Extends Survival of Adults with AML Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer
